1stOncology™: Cancer Intelligence Service – Page 12247 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

On July 16, 2020 GlyTherix Ltd (GlyTherix) reported that a consortium led by the company are the successful recipients of a competitive grant in Round 9 of the Federal Government’s Cooperative Research Centres Projects (CRC-P) program (Press release, Glytherix, JUL 16, 2020, View Source [SID1234565141]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The grant will use the company’s proprietary novel target, Glypican-1, and its lead antibody to this target, Miltuximab, as a flagship molecule to develop national capability in manufacturing and distribution of radioimmuno-oncology drugs.

Radioimmunotherapy (RIT) uses antibodies to selectively deliver radiation to kill cancer cells, while limiting damage to healthy cells.

Dr Brad Walsh, CEO of GlyTherix, said that widespread adoption of RIT has been traditionally limited by the complex manufacturing process and short shelf life of the radioisotope.

"The grant brings together Australian SMEs, universities and government research organisations to pioneer manufacturing of "shake-and-bake" kits that allow on-site, on-demand production of RITs in hospital radio-pharmacies. Our Miltuximab antibody will be used as a testbed for the entire production process, testing safety and efficacy in a Phase 1 clinical trial. This project not only builds out our data around the technology but will also lead the way for Australia to develop sovereign capability in antibody manufacturing and RIT kits. Ultimately, these kits will help facilitate expanding a theranostic approach to cancer treatment in many more hospitals and patients," said Dr Walsh.

In this project radiolabelled Miltuximab is being used for both imaging and immunotherapy, known as ‘theranostics’. The project partners include Australian Nuclear Science And Technology Organisation (ANSTO), Commonwealth Scientific And Industrial Research Organisation (CSIRO), Cytiva (formerly GE Healthcare Life Sciences), Auspep Pty Ltd, University Of Technology Sydney and Macquarie University.

Dr Walsh said that the combined experience and expertise of the project partners augurs well for a successful project.

"We are grateful to the Federal Government for recognising the internationally competitive potential in this application. It’s extremely exciting to be commencing our manufacturing and clinical trial program for Miltuximab with such an esteemed group of experts in their field from highly respected Australian and International companies and institutions," said Dr Walsh.

"Theranostics is one of the most exciting areas of medicine and an area where Australia is a world leader. This CRC-P enables the diverse skills required to be assembled locally to benefit from our world leading position in this field of medicine. The pairing of a precision diagnostic with a corresponding precision therapeutic that targets Glypican-1 has the potential to treat a wide range of cancers. We are excited to be part of the program and looking forward to working on the antibody manufacturing process at UTS." Stephen O’Sullivan, Business Development Manager – ANZ, Cytiva (formally GE Lifescience).

Professor Roger Chung from Macquarie University Faculty of Medicine, Health and Human Sciences said the University was excited to be collaborating with GlyTherix and other consortia partners on this exciting translational research project. "Through MQ Health, the University’s integrated academic health centre, we provide an important pathway for academic and industry-led technology to be evaluated in a healthcare setting towards clinical translation."

Chris Chandler MD Auspep commented that "GlyTherix has done a great job in putting this CRC-P together. They have brought the right mix of knowledge from the industrial, government and academic sectors which will give the program it’s best chance of a successful, commercial outcome."

Dr Andrew Groth, UTS Faculty of Science Business Development Manager stated the partnership was a globally significant development and the production of antibodies in the UTS Biologics Innovation Facility demonstrates the power of university and industry collaboration. "UTS is extremely proud to be part of what is a landmark for the Australian biopharmaceutical industry with an end-to-end project from development to clinical trials," he said.

"Radioimmuno-oncology is one of the most exciting and dynamic areas in nuclear medicine and radiochemistry, with robust research and commercial interest globally. This timely CRC-P will establish an end-to-end national capability for antibody-based theranostics in Australia, building our reputation as a global leader in nuclear medicine clinical trials. ANSTO is proud to be a participant in this project delivering to our core missions of improving the health of all Australians and supporting Australian business." Dr Nigel Lengkeek, Senior Radiochemist, ANSTO.

GlyTherix is looking for investors who would like to be involved in the company’s Series A funding round.

Cytokinetics Announces Pricing of Public Offering of Common Stock

On July 16, 2020 Cytokinetics, Incorporated (Nasdaq:CYTK) reported the pricing of an underwritten public offering of 7,291,667 shares of its common stock at a price to the public of $24.00 per share, before underwriting discounts and commissions (Press release, Cytokinetics, JUL 16, 2020, View Source,before%20underwriting%20discounts%20and%20commissions. [SID1234562042]). The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $175.0 million. The offering is expected to close on July 21, 2020, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,093,750 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. Barclays Capital Inc. is acting as an additional book-running manager for the offering. JMP Securities LLC is acting as lead co-manager, and Raymond James & Associates, Inc. and H.C. Wainwright & Co., LLC are acting as co-managers.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a prospectus) filed on November 6, 2019 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed, and a final prospectus supplement and accompanying prospectus relating to the offering will be filed, with the SEC and can be accessed for free on the SEC’s website at View Source Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by phone at (866) 471‐2526 or by email at [email protected]; Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, New York 10022, or by email: [email protected]; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: 1-888-603-5847.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

LIGAND’S SECOND QUARTER FINANCIAL RESULTS TO BE REPORTED AUGUST 3RD

On July 16, 2020 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that details of its plans to report second quarter 2020 financial results on August 3, 2020 (Press release, Ligand, JUL 16, 2020, View Source [SID1234562041]). Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

Second Quarter 2020 Earnings Conference Call

What:

Ligand conference call to discuss financial results and provide general business updates

Date:

Monday, August 3, 2020

Time:

8:30 a.m. Eastern time (5:30 a.m. Pacific time)

Conference Call:

Dial (833) 325-0071 within the U.S.

Dial (720) 405-1612 outside the U.S.

Conference ID is 1697855

Webcast:

Live conference call webcast and replay accessible at www.ligand.com

Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020

On July 16, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) repored that its second quarter 2020 financial results will be released on Thursday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s second quarter 2020 financial results and will provide a business update (Press release, Gilead Sciences, JUL 16, 2020, View Source [SID1234562040]).

The live webcast of the call can be accessed at the company’s Investors page at View Source Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 9561515 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, August 1, 2020. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 9561515. The webcast will be archived on www.gilead.com for one year.

Altimmune Announces Closing Of $132 Million Public Offering Of Common Stock And Pre-Funded Warrants And Full Exercise Of Underwriters’ Option

On July 16, 2020 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that its previously announced underwritten public offering of 4,119,564 shares of its common stock, and, to certain investors in lieu thereof, pre-funded warrants to purchase 1,630,436 shares of its common stock at an exercise price of $0.0001 per share (Press release, Altimmune, JUL 16, 2020, View Source [SID1234562039]). The shares include 750,000 shares of common stock sold pursuant to the option granted by the Company to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $23.00 and the public offering price of each pre-funded warrant was $22.9999 per underlying share.

The aggregate gross proceeds to Altimmune from the offering were approximately $132.2 million, which includes the exercise of the underwriters’ option to purchase additional shares in full, before deducting underwriting discounts and commissions and offering expenses payable by Altimmune. Altimmune anticipates using the net proceeds from the offering for general corporate purposes, which may include, but are not limited to, scale up of manufacturing and advanced clinical trials of AdCOVID, a single dose intranasal COVID-19 vaccine candidate; the continued development of ALT-801, its dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH), including manufacturing and clinical trials; and for capital expenditures and working capital.

Jefferies, Evercore ISI and Piper Sandler acted as joint book-running managers for the offering. Roth Capital Partners acted as co-manager for the offering.

The securities described above were offered by Altimmune pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and became effective by rule of the Securities and Exchange Commission (SEC) on April 12, 2019. A final prospectus supplement and accompanying prospectus related to the offering has been filed with the SEC and is available on the SEC’s website located at View Source Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200 or by email at [email protected]; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.